Downregulation of miR‑106b‑3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3

Zhu,Yong; Zhang,Yun; Li,Xiaohua; Su,Yuntao; Wang,Nina; Chen,Minli; Yang,Zhe

doi:10.3892/mmr.2021.12110

Downregulation of miR‑106b‑3p increases sensitivity to cisplatin in esophageal cancer cells by targeting TGM3

Authors:
- Yong Zhu
- Yun Zhang
- Xiaohua Li
- Yuntao Su
- Nina Wang
- Minli Chen
- Zhe Yang
View Affiliations

Affiliations: Radiation Therapy Department, Baoji Central Hospital, Baoji, Shaanxi 721008, P.R. China
Published online on: April 21, 2021 https://doi.org/10.3892/mmr.2021.12110
Article Number: 471

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal cancer (EC) is one of the most malignant and lethal digestive‑related tumors worldwide. However, acquired drug resistance is a major obstacle concerning anticancer chemotherapy. An increasing number of studies have reported that microRNAs (miRNAs/miRs) are implicated in regulating the sensitivity of drug resistance in esophageal squamous cell carcinoma (ESCC). The aim of the present study was to investigate the role of miR‑106b‑3p in the sensitivity of cisplatin for ESCC. Initially, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to analyze miR‑106b‑3p and protein‑glutamine γ‑glutamyltransferase E (TGM3) expression levels in ESCC and non‑tumor adjacent tissues. By using bioinformatics software TargetScan, TGM3 was predicted to be a potential downstream target of miR‑106‑3p. Following verification that TGM3 was a downstream target of miR‑106b‑3p by the dual‑luciferase reporter assay, the effects of miR‑106b‑3p transfection on KYSE30 cell viability and apoptosis following treatment with cisplatin were confirmed using Cell Counting Kit‑8 and flow cytometry assays, respectively. The results revealed that miR‑106b‑3p levels were upregulated, whereas TMG3 levels were downregulated in ESCC tissues. Dual‑luciferase reporter assays confirmed that miR‑106b‑3p negatively regulated TGM3 expression by binding to its 3'UTR sequence. It was also shown that inhibition of miR‑106b‑3p could enhance the anti‑proliferative effects, while promoting the apoptotic effects of cisplatin in the KYSE30 cell line by targeting TGM3. In conclusion, the present study demonstrated that downregulation of miR‑106b‑3p may increase the sensitivity of KYSE30 cell to cisplatin by targeting TGM3.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Kim JJ, Park JK and Moon SW: Usefulness of positron emission tomography-computed tomography in pre-operative evaluation of intra-thoracic esophageal cancer. Thorac Cancer. 6:687–694. 2015. View Article : Google Scholar : PubMed/NCBI
3	Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Mori M and Doki Y: Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 18:3353–3361. 2011. View Article : Google Scholar : PubMed/NCBI
4	Akutsu Y and Matsubara H: Chemotherapy and surgery for T4 esophageal cancer in Japan. Surg Today. 45:1360–1365. 2015. View Article : Google Scholar : PubMed/NCBI
5	Martens-Uzunova ES, Olvedy M and Jenster G: Beyond microRNA-novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Lett. 340:201–211. 2013. View Article : Google Scholar : PubMed/NCBI
6	Lu C, Shan Z, Li C and Yang L: miR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 86:450–456. 2017. View Article : Google Scholar : PubMed/NCBI
7	Mutlu M, Raza U, Saatci O, Eyupoglu E, Yurdusev E and Sahin O: miR-200c: A versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med (Berl). 94:629–644. 2016. View Article : Google Scholar : PubMed/NCBI
8	Lang B, Shang C and Meng L: Targeted silencing of S100A8 gene by miR-24 increase chemotherapy sensitivity of endometrial carcinoma cells to paclitaxel. Med Sci Monit. 22:1953–1958. 2016. View Article : Google Scholar : PubMed/NCBI
9	Sun C, Yao X, Jiang Q and Sun X: miR-106b targets DAB2 to promote hepatocellular carcinoma cell proliferation and metastasis. Oncol Lett. 16:3063–3069. 2018.PubMed/NCBI
10	Bu W, Wang Y and Min X: microRNA-106b promotes the proliferation, migration and invasion of retinoblastoma cells by inhibiting the expression of ZBTB4 protein. Exp Ther Med. 16:4537–4545. 2018.PubMed/NCBI
11	Jiao D, Yan Y, Shui S, Wu G, Ren J, Wang Y and Han X: miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma. Oncotarget. 8:52913–52922. 2017. View Article : Google Scholar : PubMed/NCBI
12	Dai F, Liu T, Zheng S, Liu Q, Yang C, Zhou J, Chen Y, Shehidin I and Lu X: miR-106b promotes migration and invasion through enhancing EMT via downregulation of Smad 7 in Kazakh's esophageal squamous cell carcinoma. Tumor Biol. 37:14959–14604. 2016. View Article : Google Scholar
13	Yu S, Qin X, Chen T, Zhou L, Xu X and Feng J: microRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anticancer Drugs. 28:852–860. 2017. View Article : Google Scholar : PubMed/NCBI
14	Yao GD, Zhang YF, Chen P and Ren XB: MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1. Oncol Lett. 15:991–997. 2018.PubMed/NCBI
15	Long XH, Shi Y, Ye P, Guo J, Zhou Q and Tang YT: MicroRNA-99a suppresses breast cancer progression by targeting FGFR3. Front Oncol. 9:14732019. View Article : Google Scholar : PubMed/NCBI
16	Ni SJ, Weng WW, Xu MD, Wang QF, Tan C, Sun H, Wang L, Huang D, Du X and Sheng WQ: miR-106b-5p inhibits the invasion and metastasis of colorectal cancer by targeting CTSA. Onco Targets Ther. 11:3835–3845. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhou YT, Tian WH, Zhang M, Ren TH, Sun GR, Jiang RR, Han RL, Kang XT and Yan FB: Transcriptom analysis revealed regulation of dexamethasone induced microRNAs in chicken thymus. J Cell Biochem. 120:6570–6579. 2019. View Article : Google Scholar : PubMed/NCBI
18	Wu XB, Cao W, Wang X, Zhang JJ, Lv ZJ, Qin X, Wu YD and Chen WT: TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer. Mol Cancer. 12:1512013. View Article : Google Scholar : PubMed/NCBI
19	Feng Y, Ji D, Huang Y, Ji B, Zhang Y, Li J, Peng W, Zhang C, Zhang D, Sun Y and Xu Z: TGM3 functions as a tumor suppressor by repressing epithelial-to-mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer. Oncol Rep. 43:864–876. 2020.PubMed/NCBI
20	Livak KJ and Schimittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wu J, Wang L, Du X, Sun Q, Wang Y, Li M, Zang W, Liu K and Zhao G: α-solanine enhances the chemosensitivity of esophageal cancer cells by inducing microRNA-138 expression. Oncol Rep. 39:1163–1172. 2018.PubMed/NCBI
22	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
23	Steven AC and Steinert PM: Protein composition of cornified cell envelopes of epidermal keratinocytes. J Cell Sci. 107:693–700. 1994. View Article : Google Scholar : PubMed/NCBI
24	Luo A, Kong J, Hu G, Liew CC, Xiong M, Wang X, Ji J, Wang T, Zhi H, Wu M and Liu Z: Discovery of CA2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncotarget. 23:1291–1299. 2004.PubMed/NCBI
25	Wu X, Cao W, Wang X, Zhang J, Lv Z, Qin X, Wu Y and Chen W: TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer. Mol Cancer. 12:1512013. View Article : Google Scholar : PubMed/NCBI
26	Wu X, Wang R, Jiao J, Li S, Yu J, Yin Z, Zhou L and Gong Z: Transglutaminase 3 contributes to malignant transformation of oral leukoplakia to cancer. Int J Biochem Cell Biol. 104:34–42. 2018. View Article : Google Scholar : PubMed/NCBI
27	He G, Zhao Z, Fu W, Sun X, Xu Z and Sun K: Study on the loss of heterozygosity and expression of transglutaminase 3 gene in laryngeal carcinoma. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 19:120–123. 2002.(In Chinese). PubMed/NCBI
28	Negishi A, Masuda M, Ono M, Honda K, Shitashige M, Satow R, Sakuma T, Kuwabara H, Nakanishi Y, Kanai K, et al: Quantitative proteomics using formalin-fixed paraffin-embedded tissues of oral squamous cell carcinoma. Cancer Sci. 100:1605–1611. 2009. View Article : Google Scholar : PubMed/NCBI
29	Stacey SN, Sulem P, Gudbjartsson DF, Jonasdottir A, Thorleifsson G, Gudjonsson SA, Masson G, Gudmundsson J, Sigurgeirsson B, Benediktsdottir KR, et al: Germline sequence variants in TGM3 and RGS22 confer risk of basal cell carcinoma. Hum Mol Genet. 23:3045–3053. 2014. View Article : Google Scholar : PubMed/NCBI
30	Liu W, Yu ZC, Cao WF, Ding F and Liu ZH: Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma. World J Gastroenterol. 12:3929–3932. 2006. View Article : Google Scholar : PubMed/NCBI
31	Li W, Zhang Z, Zhao W and Han N: Transglutaminase 3 protein modulated human esophageal cancer cell growth by targeting the NF-κB signaling pathway. Oncol Rep. 36:1723–1730. 2016. View Article : Google Scholar : PubMed/NCBI
32	Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S and Kondo T: Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 124:2106–2115. 2009. View Article : Google Scholar : PubMed/NCBI
33	Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 33:981–989. 2015. View Article : Google Scholar : PubMed/NCBI
34	Zheng TL, Li DP, He ZF and Zhao S: miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int. 19:2502019. View Article : Google Scholar : PubMed/NCBI
35	Lin WC, Chen LH, Hsieh YC, Yang PW, Lai LC, Chuang EY, Lee JM and Tsai HM: miR-338-5p inhibits cell proliferation, colony formation, migration and cisplatinresistance in esophageal squamous cancer cells by targeting FERMT2. Carcinogenesis. 40:883–892. 2019. View Article : Google Scholar : PubMed/NCBI
36	Zhao Y, Ma K, Yang S, Zhang X, Wang F, Zhang X, Liu H and Fan Q: MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int J Oncol. 53:644–658. 2018.PubMed/NCBI
37	Fang Y, Zhou W, Rong Y, Kuang T, Xu X, Wu W, Wang D and Lou W: Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Exp Cell Res. 383:1115432019. View Article : Google Scholar : PubMed/NCBI